Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter
复制标题
齐多夫定用于无症状 HIV 感染且 CD4 细胞计数大于 400 每立方毫米的患者
DOI：
--
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
A. Fiddian
中科院分区：
文献类型：
--
作者：
D. Cooper;J. Gatell;S. Kroon;N. Clumeck;J. Millard;F. Goebel;J. Bruun;G. Stingl;R. Melville;J. González;J. Stevens;A. Fiddian
背景
齐多夫定疗法对治疗CD4 +细胞计数低于每立方毫米500个的有症状和无症状的人类免疫缺陷病毒（HIV）感染者有益。齐多夫定在CD4 +细胞计数为每立方毫米500个或更多的患者中的疗效、安全性以及受益持续时间尚不确定。
方法
在一项双盲、安慰剂对照试验中，993例无症状HIV感染且CD4 +细胞计数高于每立方毫米400个的患者被随机分配接受齐多夫定（每日两次，每次500毫克）或安慰剂治疗三年。主要终点是疾病进展，其定义为出现疾病控制与预防中心（CDC）IV组疾病（包括复发性口腔念珠菌病、毛状白斑或进行性腹泻）或两次CD4 +细胞计数低于每立方毫米350个。这一结果衡量指标从最初的获得性免疫缺陷综合征（AIDS）或晚期艾滋病相关综合征的终点改为……
Background Zidovudine therapy is of benefit in the treatment of symptomatic and asymptomatic human immunodeficiency virus (HIV) infection in persons with CD4+ cell counts of less than 500 per cubic millimeter. The efficacy, safety, and duration of benefit of zidovudine in those with 500 or more CD4+ cells per cubic millimeter are uncertain. Methods In a double-blind, placebo-controlled trial, 993 patients with asymptomatic HIV infection and CD4+ cell counts above 400 per cubic millimeter were randomly assigned to receive zidovudine (500 mg twice daily) or placebo for three years. The primary end point was progression of disease, as defined by the development of Centers for Disease Control and Prevention (CDC) group IV disease (including recurrent oral candidiasis, hairy leukoplakia, or progressive diarrhea) or two CD4+ cell counts below 350 per cubic millimeter. This outcome measure was changed from the original end point of the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex to...
影响因子：
158.5
作者：
HO, DD;MOUDGIL, T;ALAM, M
通讯作者：
ALAM, M
疾病阶段和药物剂量对人类免疫缺陷病毒分离株齐多夫定敏感性的影响。
DOI：
--
发表时间：
1990
期刊：
Journal of acquired immune deficiency syndromes
影响因子：
--
作者：
Richman,DD;Grimes,JM;Lagakos,SW
通讯作者：
Lagakos,SW